Log In
BCIQ
Print this Print this
 

LPCN 1021

  Manage Alerts
Collapse Summary General Information
Company Lipocine Inc.
DescriptionOral formulation of testosterone that uses Lipocine's Lip'ral oral delivery technology
Molecular Target
Mechanism of ActionHormone replacement therapy
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationHypogonadism
Indication DetailsTreat hypogonadism
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today